{"title":"褪黑素作为帕金森病睡眠障碍的一线治疗?","authors":"C. Cox, A. Mackett","doi":"10.1002/pnp.728","DOIUrl":null,"url":null,"abstract":"Sleep disturbance has been reported in up to 88%–98% of Parkinson's disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behaviour disorder (RBD), which can lead to violent dream enactment behaviour, has a prevalence in Parkinson's disease of 20% to 50% but best management of the condition is unclear. Here, the authors consider whether melatonin is an effective pharmacological option to manage RBD.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Melatonin as first‐line treatment for sleep disorders in Parkinson's disease?\",\"authors\":\"C. Cox, A. Mackett\",\"doi\":\"10.1002/pnp.728\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sleep disturbance has been reported in up to 88%–98% of Parkinson's disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behaviour disorder (RBD), which can lead to violent dream enactment behaviour, has a prevalence in Parkinson's disease of 20% to 50% but best management of the condition is unclear. Here, the authors consider whether melatonin is an effective pharmacological option to manage RBD.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.728\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.728","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Melatonin as first‐line treatment for sleep disorders in Parkinson's disease?
Sleep disturbance has been reported in up to 88%–98% of Parkinson's disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behaviour disorder (RBD), which can lead to violent dream enactment behaviour, has a prevalence in Parkinson's disease of 20% to 50% but best management of the condition is unclear. Here, the authors consider whether melatonin is an effective pharmacological option to manage RBD.
期刊介绍:
Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.